Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472560 · ClinicalTrials.gov registry record · Phase 2
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03472560 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 61 participants.
The verdict
NCT03472560, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.
Interventions
- DRUG Axitinib (AG-013736)
- DRUG Avelumab (MSB0010718C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472560
The ClinicalTrials.gov registry entry for NCT03472560 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib (AG-013736) is the first listed.
NCT03472560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472560 about?
NCT03472560 is a clinical study titled "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)". This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastati...
What is the current status of trial NCT03472560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-05-02. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT03472560?
The interventions under investigation include: Axitinib (AG-013736) (DRUG), Avelumab (MSB0010718C) (DRUG).
Who is sponsoring clinical trial NCT03472560?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.